Pandemic-era NIH grants (FY2019-2024) covering coronavirus, gain-of-function research, mRNA vaccines, biosafety, and related funding flows. Metadata + abstracts from NIH RePORTER.
Get an AI answer drawn only from the NIH Pandemic-Era Grants documents indexed here — every claim cited back to the filing or proceeding it came from. It will tell you plainly when the record doesn't cover your question, rather than guessing.
Yu-Hua Tseng · JOSLIN DIABETES CENTER · 2022 · $575,674 — Project Summary/Abstract Obesity is growing at epidemic rates worldwide and leads to a broad spectrum of other disorders, which collectively form metabolic syndrome. Central to these pathologies is the adipose tissue. In mammals, there are two functionally distinct types of fat: white adipose tissu…
Reyad A Elbarbary · PENNSYLVANIA STATE UNIV HERSHEY MED CTR · 2022 · $395,786 — Abstract Impaired or delayed fracture healing is a clinical problem that affects >1.5 million people in the US annually; obesity and associated type 2 diabetes (T2D) are significant and independent risk factors in this context. Nearly 34% of the US population is obese, and the number is projected to…
James Dahlman · GEORGIA INSTITUTE OF TECHNOLOGY · 2022 · $100,741 — Project Summary Scientists can create thousands of chemically distinct nanoparticles using a growing number of high throughput chemistries, but it is still difficult to test more than a few nanoparticles in vivo. The goal of this work is to substantially improve how lipid nanoparticles (LNPs) delive…
Kerry S Campbell · THOMAS JEFFERSON UNIVERSITY · 2022 · $506,466 — Project Summary NK cells are capable of killing virus-infected and cancer cells and, therefore, play an important role in innate host defense. Unlike cytotoxic T lymphocytes (CTL), whose cytolytic activity is induced by productive TCR engagement with cognate pMHC ligands, activation of NK cells is r…
Bulent Ozpolat · METHODIST HOSPITAL RESEARCH INSTITUTE · 2022 · $390,063 — Project Summary Triple-negative breast cancer (TNBC) has the highest patient death rate of all breast cancer subtypes. Several molecular targets have been identified for breast cancer treatment, but currently, there is no approved, broadly applicable targeted therapy for TNBC. Through 10 years of re…
ANUP KUMER KUNDU · XAVIER UNIVERSITY OF LOUISIANA · 2022 · $112,500 — ABSTRACT The development of multidrug resistance (MDR) in cancer cells is of grave concern, limiting the efficacy of anticancer agents and, hence, the failure of breast cancer therapy. Clinical research and application revealed that in spite of its potential anticancer effects, doxorubicin is highly…
Weihua Qiu · VIRGINIA COMMONWEALTH UNIVERSITY · 2022 · $194,063 — SUMMARY Connexin 26, as a gap junction channel, directly regulates the cell-to-cell exchange of ion, metabolites, and second messengers. Mutations of connexin 26 can cause severe hearing loss. However, the molecular gating mechanism on the structural basis of connexin 26 is still unclear, especially…
Marco E Zamora · DREXEL UNIVERSITY · 2022 · $46,752 — Proposal Summary/Abstract Acute respiratory distress syndrome (ARDS) is an acute inflammation of the lungs. It represents 10% of all intensive care unit (ICU) admissions in the United States. Despite decades of research and numerous large clinical trials, there are few treatments for ARDS. This lack…
Peng Zhang · NORTHWESTERN UNIVERSITY AT CHICAGO · 2022 · $366,000 — PROJECT SUMMARY/ABSTRACT Radiation therapy (RT) is a key component of standard of care treatments for glioblastoma (GBM), the most common and deadly primary brain malignancy in adults. Beyond the direct cytotoxic effect on tumor itself, RT- elicited anti-tumor immune responses have recently been app…
Jian-Xing Jay Ma · VIRGINIA COMMONWEALTH UNIVERSITY · 2022 · $551,841 — PROJECT SUMMARY Diabetic retinopathy (DR) is the most common cause of severe vision loss in the working-age population in the world. However, clinical studies have shown that approximately 40% DR patients do not adequately respond to anti-VEGF drugs. There is no drug treatment for those 40% DR pati…
William H. Peranteau · CHILDREN'S HOSP OF PHILADELPHIA · 2022 · $738,367 — PROJECT SUMMARY Metabolic liver diseases are the second most common indication for a pediatric liver transplant. Hereditary tyrosinemia type I (HT1) is a metabolic liver disease that results from FAH gene mutations causing a deficiency in fumarylacetoacetate hydrolase (FAH), the last enzyme in the t…
ROBERT G BENNETT · OMAHA VA MEDICAL CENTER · 2022 — Metabolic disorders, such as obesity, are associated with adipose tissue hypoxia, inflammation and fibrosis, and impaired lipid uptake, causing ectopic lipid uptake other organs, such as the liver. Furthermore, the secreted adipokine profile changes dramatically, with impaired secretion of antifibro…
Aaron Clifford Brown · MAINEHEALTH · 2022 · $430,000 — Project Summary/Abstract The obesity epidemic is a global public health issue, that leads to an increased risk for type 2 diabetes and cardiovascular disease. Hypertrophy, inflammation, and excess lipid accumulation in white adipocytes within fat tissue are hallmarks of obesity that contribute to me…
Rohan Palanki · UNIVERSITY OF PENNSYLVANIA · 2022 · $51,752 — PROJECT SUMMARY Congenital lung diseases, such as inherited surfactant protein syndromes, cystic fibrosis, and alpha-1 antitrypsin deficiency, are a significant source of pediatric morbidity and mortality. Treatment options for neonatal patients with lung disorders that present with respiratory fail…
Adam G Berger · HARVARD MEDICAL SCHOOL · 2022 · $51,752 — Project Summary Non-healing ulcers are a common complication of diabetes, resulting in decreased quality of life, elevated rates of amputation, increased risk of mortality, and high healthcare costs. Unfortunately, current treatments remain outdated and inadequate. In diabetes, neuropathy and microv…
Olga Gursky · BOSTON UNIVERSITY MEDICAL CAMPUS · 2022 · $436,764 — Abstract Aberrant lipoprotein metabolism is a hallmark of obesity that affects >40% of Americans. Obesity and its com- plications, including type-2 diabetes (T2D), cardiovascular, amyloid and severe viral diseases, are the leading causes of premature death. The ultimate goal of this research is to …
Robert Frederick Pagels · OPTIMEOS LIFE SCIENCES, INC. · 2022 · $287,726 — Peptides can have exquisite potency and selectivity in treating disease, but suffer from rapid clearance. Microparticle depot formulations, where the peptide is entrapped in a water-insoluble polymer matrix, have been tested for decades to provide sustained therapeutic release for chronic disease. T…
Jagadeesh Ramasamy · UNIVERSITY OF ILLINOIS AT CHICAGO · 2022 · $455,195 — PROJECT SUMMARY/ABSTRACT The long-term objective of this proposal is to develop non-opioid novel molecular targets to reduce the pain suffering and mortality attributed to sickle cell disease (SCD), by identifying to upstream messengers of acute and chronic pain signaling. Mitochondrial retention in…
Arif Yurdagul · LOUISIANA STATE UNIV HSC SHREVEPORT · 2022 · $249,000 — Atherosclerotic cardiovascular disease (CVD) is the leading cause of death in the industrialized world. Most atherosclerotic plaques are clinically silent; however, a subset can lead to myocardial infarction, stroke, or sudden death. Atheromas that are linked to clinical events are characterized by …
Efstathios Karathanasis · CASE WESTERN RESERVE UNIVERSITY · 2022 · $578,640 — PROJECT SUMMARY First-line chemotherapy is the standard of care for patients with triple-negative breast cancer (TNBC). While short-term response is achievable, most patients succumb to recurrence due to metastasis. Micrometastasis encompasses a small population of dormant disseminated tumor cells (…